Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Brazil / NCT06179329
Recruiting Not applicable

One-year Patency Comparison Between Radial Artery and No-touch Saphenous Vein Grafts in Women Undergoing Isolated CABG

NCT06179329 · tracked via the Priya Life Science Brazil tracker
Phase
Not applicable
Started
2024-01-01
Last updated
2025-12-12

Condition(s) studied

Cardiac DiseaseSurgery-ComplicationsGraft Failure

Investigational drug(s) / intervention(s)

Coronary artery bypass graft

Coronary artery bypass graft: Randomization will be performed for stratification according to the target coronary arteries and the randomly determined block size from 4 to 6. The randomization result will be delivered in a sealed envelope in the operating room (before the time out) for one of the two drawn strategies.

Study summary

The use of a graft from the left internal thoracic artery to the left anterior descending artery has become the gold standard for the indication of coronary artery bypass grafting. However, choosing a graft for the second-best coronary artery, focusing on long-term patency, is still a challenge. The saphenous vein using the "no-touch" technique is an alternative to a radial artery graft, but there is little evidence, especially in women. This randomized clinical study aims to compare the patency of these grafts in the second-best coronary artery in women undergoing coronary artery bypass grafting.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: Women aged 18 years or older and younger than 75 years, undergoing isolated and primary myocardial revascularization surgery, with triarterial coronary artery disease (three vessels involved) in vessels subject to surgical revascularization and left ventricular ejection fraction greater than 35%. The target coronary vessels of the study will be those in the territory of the left circumflex artery and the right coronary artery, which must have at least 1.5 mm in diameter, and with proximal obstructive lesions of at least 70%. Exclusion Criteria: 1. Preoperative conditions: 1. Lack of the patient's written informed consent. 2. Presence of poorly controlled diabetes, with a glycated hemoglobin value \>8 mg/dl. 3. Emergency or salvage surgery, where the intervention needs to be performed quickly due to the critical clinical condition of the patient. 4. Renal failure with glomerular filtration rate (creatinine clearance) \<30 mL/min. 2. Inability to use the saphenous and/or radial vein 1. Positive Allen test using a pulse oximeter 2. Presence of abnormal flow detected by means of a Doppler exam in one of the grafts to be used. 3. History of vasculitis or Raynaud's syndrome, varicose veins, or history of previous saphenous vein removal 3. Conditions that may affect patient follow-up 1. Presence of advanced peripheral arterial disease 2. Known contrast allergy: Presence of a documented allergy to the contrast agent used in radiological procedures. 3. Impossibility of tracking due to geographic inaccessibility. 4. Patients with lack of adherence to guidelines and/or prescribed medications.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Instituto do Coração do Hospital das Clínicas da Faculdade de Medicina de São Paulo São Paulo São Paulo Recruiting

More University of Sao Paulo General Hospital trials in Brazil

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06179329 on ClinicalTrials.gov ↗ ← All trials in Brazil